| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Hypothermia | D007035 | 19 associated lipids |
Total
3
noladin ether
Noladin ether is a lipid of Glycerolipids (GL) class. The involved functions are known as 5-(carboxyamino)imidazole ribonucleotide mutase activity and Competitive inhibition. Noladin ether often locates in Synaptosomes and Tissue membrane. The associated genes with Noladin Ether are IMPACT gene. The related lipids are noladin ether and Fatty Alcohols.
Cross Reference
Introduction
To understand associated biological information of noladin ether, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with noladin ether?
There are no associated biomedical information in the current reference collection.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with noladin ether
PubChem Associated disorders and diseases
What pathways are associated with noladin ether
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with noladin ether?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with noladin ether?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with noladin ether?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with noladin ether?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with noladin ether?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with noladin ether
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| pmid: | ||||
| Richardson D et al. | Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. | 2007 | Anal. Biochem. | pmid:17141174 |
| Hayase T et al. | Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. | 2005 | Behav Pharmacol | pmid:16148444 |
| Marichal-Cancino BA et al. | Blockade of GPR55 in the dorsolateral striatum impairs performance of rats in a T-maze paradigm. | 2016 | Behav Pharmacol | pmid:26292188 |
| Zhang Y et al. | Orphan nuclear receptor oestrogen-related receptor γ (ERRγ) plays a key role in hepatic cannabinoid receptor type 1-mediated induction of CYP7A1 gene expression. | 2015 | Biochem. J. | pmid:26348907 |
| Appendino G et al. | Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat cannabinoid CB(1) receptors. | 2003 | Bioorg. Med. Chem. Lett. | pmid:12467613 |
| Sun Y et al. | Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. | 2007 | Br. J. Pharmacol. | pmid:17906680 |
| Ryberg E et al. | The orphan receptor GPR55 is a novel cannabinoid receptor. | 2007 | Br. J. Pharmacol. | pmid:17876302 |
| Ho WS and Randall MD | Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. | 2007 | Br. J. Pharmacol. | pmid:17245358 |
| Duncan M et al. | Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor. | 2004 | Br. J. Pharmacol. | pmid:15148262 |
| Jones EK and Kirkham TC | Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats. | 2012 | Br. J. Pharmacol. | pmid:22309979 |
| Avraham Y et al. | Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. | 2005 | Brain Res. Bull. | pmid:15763177 |
| Su JY and Vo AC | 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. | 2007 | Eur. J. Pharmacol. | pmid:17292352 |
| Venderova K et al. | Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. | 2005 | Exp. Neurol. | pmid:15899265 |
| Fezza F et al. | Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. | 2002 | FEBS Lett. | pmid:11904167 |
| Laine K et al. | Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. | 2002 | Invest. Ophthalmol. Vis. Sci. | pmid:12356827 |
| Njie YF et al. | Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. | 2006 | Invest. Ophthalmol. Vis. Sci. | pmid:16639008 |
| Sancho R et al. | Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. | 2005 | J. Immunol. | pmid:16148147 |
| MartÃn-Couce L et al. | Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors. | 2011 | J. Med. Chem. | pmid:21675776 |
| Brizzi A et al. | Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor. | 2011 | J. Med. Chem. | pmid:22044209 |
| Juntunen J et al. | Synthesis, in vitro evaluation, and intraocular pressure effects of water-soluble prodrugs of endocannabinoid noladin ether. | 2003 | J. Med. Chem. | pmid:14584958 |
| Oka S et al. | Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. | 2003 | J. Neurochem. | pmid:12787057 |
| Shoemaker JL et al. | Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. | 2005 | J. Pharmacol. Exp. Ther. | pmid:16081674 |
| Shoemaker JL et al. | The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. | 2005 | J. Pharmacol. Exp. Ther. | pmid:15901805 |
| Shimizu T et al. | Stimulatory and inhibitory roles of brain 2-arachidonoylglycerol in bombesin-induced central activation of adrenomedullary outflow in rats. | 2013 | J. Pharmacol. Sci. | pmid:23386378 |
| Straiker A and Mackie K | Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. | 2005 | J. Physiol. (Lond.) | pmid:16179366 |
| van der Stelt M et al. | Acute neuronal injury, excitotoxicity, and the endocannabinoid system. | 2002 Oct-Dec | Mol. Neurobiol. | pmid:12428763 |
| Guo J and Ikeda SR | Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. | 2004 | Mol. Pharmacol. | pmid:14978245 |
| Kumar A and Song ZH | CB1 cannabinoid receptor-mediated changes of trabecular meshwork cellular properties. | 2006 | Mol. Vis. | pmid:16617296 |
| Páldy E et al. | CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. | 2008 | Neurochem. Int. | pmid:18804501 |
| Páldyová E et al. | Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. | 2008 | Neurochem. Int. | pmid:17698254 |
| Unzicker C et al. | Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: a neuroprotective substitution effect? | 2005 | Neurochem. Res. | pmid:16341592 |
| Izumi Y and Zorumski CF | NMDA receptors, mGluR5, and endocannabinoids are involved in a cascade leading to hippocampal long-term depression. | 2012 | Neuropsychopharmacology | pmid:21993209 |
| Milton NG | Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. | 2002 | Neurosci. Lett. | pmid:12384227 |
| Maison P et al. | BDNF regulates neuronal sensitivity to endocannabinoids. | 2009 | Neurosci. Lett. | pmid:19818836 |
| Deshmukh RR and Sharma PL | Stimulation of accumbens shell cannabinoid CB(1) receptors by noladin ether, a putative endocannabinoid, modulates food intake and dietary selection in rats. | 2012 | Pharmacol. Res. | pmid:22728691 |
| Iannotti FA et al. | The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels. | 2014 | Proc. Natl. Acad. Sci. U.S.A. | pmid:24927567 |
| Hanus L et al. | 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11259648 |
| Nithipatikom K et al. | Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. | 2011 | Prostaglandins Other Lipid Mediat. | pmid:21167293 |